PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.Therapeutic advances in medical oncology · 2023
   Article
2. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.Frontiers in immunology · 2022
   Review
3. SARS-COV-2 infection and lung tumor microenvironment.Molecular biology reports · 2021
   Review
4. Regulatory B cells in respiratory health and diseases.Immunological reviews · 2021
   Review
5. Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer.Journal of thoracic disease · 2020
   Article
6. Interval between planning and frameless stereotactic radiosurgery for brain metastases: are our margins still accurate?Neuro-oncology practice · 2020
   Article
7. Systematic analysis of the transcriptome in small-cell carcinoma of the oesophagus reveals its immune microenvironment.Clinical & translational immunology · 2020
   Article
8. Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB).OncoTargets and therapy · 2019
   Article
9. Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma.Frontiers in oncology · 2019
   Review
10. Combining radiation plus immunotherapy to improve systemic immune response.Journal of thoracic disease · 2018
    Review
11. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.Frontiers in immunology · 2018
    Review

Corrections and comments

• Comment on
  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.